Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
Veru Inc., a NASDAQ-listed late clinical stage biopharmaceutical company, announced its CEO will participate in a fireside chat at the Canaccord Genuity's 46th Annual Growth Investors Conference. The company is advancing its Phase 2b PLATEAU clinical study investigating enobosarm in combination with GLP-1 receptor agonists for improved weight loss …